ECOG-ACRIN EA3163 Trial Details
ECOG-ACRIN EA3163 was a randomized phase II trial investigating neoadjuvant chemotherapy followed by surgery versus surgery alone for organ preservation in T3/T4a nasal and paranasal sinus squamous cell carcinoma with anterior skull base involvement 1.
Study Design
This was a randomized controlled trial comparing two treatment approaches:
- Arm A (Control): Surgery alone
- Arm B (Experimental): Three cycles of docetaxel/cisplatin neoadjuvant chemotherapy followed by surgery
The trial required assessment of anticipated structure preservation (orbit and base of skull) both preoperatively and after chemotherapy, with final preservation documented at surgery 1.
Eligibility Criteria
Included patients had:
- T3/T4a nasal and paranasal sinus squamous cell carcinoma
- Select T4b disease
- Tumors requiring orbital or base of skull (BOS) resection
- Disease amenable to surgical resection 1
Primary and Secondary Endpoints
Co-primary objectives:
- Structure preservation (SP) rate for orbit and base of skull
- Overall survival (OS)
The trial was designed to accrue 82 patients with 81% power (one-sided alpha 0.1) for SP rate using Fisher's exact test, and 83% power (one-sided alpha 0.1) for OS using log-rank test 1.
Key Results
Overall Population (23 evaluable patients):
- Overall SP rate: 30%
- Arm A (surgery alone): 15% (2/13 patients; 95% CI: 1.9%-45.4%)
- Arm B (neoadjuvant chemo + surgery): 50% (5/10 patients; 95% CI: 18.7%-81.3%)
- P = 0.17 (not statistically significant) 1
Pathologic T3/T4a Subgroup (18 patients):
This subgroup showed statistically significant benefit:
- Overall SP rate: 39%
- Arm A: 18% (2/11 patients; 95% CI: 2.3%-51.8%)
- Arm B: 71% (5/7 patients; 95% CI: 29.0%-96.3%)
- P = 0.049 (statistically significant) 1
Structure-Specific Preservation Rates (Arm A vs B):
- Orbit preservation: 38% vs 83%
- Base of skull preservation: 33% vs 67% 1
Safety Profile
Toxicity was manageable with no treatment-related deaths:
- Most common grade ≥3 toxicities (all >10%):
- Mucositis
- Anemia
- Nausea
- Lymphopenia
- No grade 5 (fatal) events reported 1
Clinical Implications
The trial was closed early due to poor accrual (only 23 of 82 planned patients enrolled), limiting definitive conclusions. However, the pathologic T3/T4a subgroup analysis demonstrated a statistically significant 4-fold improvement in structure preservation with neoadjuvant chemotherapy (71% vs 18%, P = 0.049) 1.
These results support neoadjuvant chemotherapy as an effective intervention for structure preservation in T3/T4a nasal and paranasal sinus squamous cell carcinoma, particularly when orbital or skull base resection would otherwise be required. The authors concluded this approach deserves further evaluation despite early trial closure 1.
Important Caveats:
- Small sample size limits generalizability
- Trial closed prematurely before reaching target accrual
- Survival data not yet mature at time of publication
- Results most robust for pathologic T3/T4a disease, not the broader T4b population initially included